Vaccine for malignant brain tumors: Update on phase II trial

An immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor, a Phase II clinical trial by an international team of researchers has demonstrated. "This is the first placebo-controlled, randomized study of a vaccine for glioblastoma to show a significant benefit in a clinically meaningful endpoint, progression-free survival. In addition, the subgroup of patients with unmethylated MGMT promoter and HLA-A2 appear to par...